- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06358651
Aerosol nasal de fasedienol para el tratamiento agudo de la ansiedad en adultos con trastorno de ansiedad social (PALISADE-3) (PALISADE-3)
EE. UU., ensayo clínico de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo del aerosol nasal de fasedienol para el tratamiento agudo de la ansiedad inducida por un desafío de hablar en público en sujetos adultos con trastorno de ansiedad social, con una extensión de etiqueta abierta (PALISADE -3)
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PALISADE-3 and choose to enter the distinct open-label extension phase of the study.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85012
- Vistagen Clinical Site
-
-
Arkansas
-
Fayetteville, Arkansas, Estados Unidos, 72703
- Vistagen Clinical Site
-
Little Rock, Arkansas, Estados Unidos, 72211
- Vistagen Clinical Site
-
-
California
-
Lafayette, California, Estados Unidos, 94549
- Vistagen Clinical Site
-
Oceanside, California, Estados Unidos, 92056
- Vistagen Clinical Site
-
Sherman Oaks, California, Estados Unidos, 91403
- Vistagen Clinical Site
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80209
- Vistagen Clinical Site
-
-
Connecticut
-
Cromwell, Connecticut, Estados Unidos, 06416
- Vistagen Clinical Site
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32256
- Vistagen Clinical Site
-
Lakeland, Florida, Estados Unidos, 33803
- Vistagen Clinical Site
-
Orlando, Florida, Estados Unidos, 32801
- Vistagen Clinical Site
-
West Palm Beach, Florida, Estados Unidos, 33407
- Vistagen Clinical Site
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Vistagen Clinical Site
-
-
Kansas
-
Overland Park, Kansas, Estados Unidos, 66210
- Vistagen Clinical Site
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21208
- Vistagen Clinical Site
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02131
- Vistagen Clinical Site
-
-
Missouri
-
Saint Charles, Missouri, Estados Unidos, 63304
- Vistagen Clinical Site
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89119
- Vistagen Clinical Site
-
-
New York
-
New York, New York, Estados Unidos, 10128
- Vistagen Clinical Site
-
-
Pennsylvania
-
Media, Pennsylvania, Estados Unidos, 19063
- Vistagen Clinical Site
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38119
- Vistagen Clinical Site
-
-
Texas
-
Fort Worth, Texas, Estados Unidos, 76104
- Vistagen Clinical Site
-
-
Utah
-
Draper, Utah, Estados Unidos, 84020
- Vistagen Clinical Site
-
-
Washington
-
Everett, Washington, Estados Unidos, 98201
- Vistagen Clinical Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Written informed consent provided prior to conducting any study specific assessment.
- Male and female adults, 18 through 65 years of age, inclusive.
- Current diagnosis of SAD as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), and confirmed by the Mini-International Neuropsychiatric Interview (MINI).
- Clinician-rated Liebowitz Social Anxiety Scale (LSAS) total score ≥70 at Screening (Visit 1).
- Clinician-rated Hamilton Depression Rating Scale (HAM-D) (17-items) total score <16.
- Female subjects of childbearing potential must be able to commit to the consistent and correct use of an effective method of birth control throughout the study
- Subjects must have normal olfactory function
Exclusion Criteria:
- Any history of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, psychosis, anorexia or bulimia, premenstrual dysphoric disorder, autism spectrum disorder, or obsessive-compulsive disorder.
- Any other current principal or personality disorder (previously known as Axis I or Axis II disorders), except for specific phobias or generalized anxiety disorder, provided that these are not the primary diagnosis.
- Subjects who meet criteria for moderate or severe alcohol use disorder within the 1 year prior to study entry, or any use of illicit substances or tetrahydrocannabinol ("THC") within 2 months prior to study entry.
- In the opinion of the investigator, the subject has a significant risk for suicidal behavior during the course of their participation in the study, or the subject is considered to be an imminent danger to themself or others.
- Clinically significant nasal pathology or history of significant nasal trauma, nasal surgery, total anosmia, or nasal septum perforation that may have damaged the nasal chemosensory epithelium.
- Two or more documented failed adequate treatment trials with a registered medication approved for SAD.
- Currently receiving cognitive-behavioral therapy (CBT), exposure therapy, or acceptance and commitment therapy.
- Subjects taking psychotropic medications within 30 days before Visit 2
- Use of any over-the-counter product, prescription product, off-label treatment, cannabidiol ("CBD"), or herbal preparation for treatment of the symptoms of anxiety or social anxiety within 30 days before Visit 2.
- Prior participation in a clinical trial involving fasedienol.
- Participation in any other clinical trial within the last 30 days or during the course of the current trial.
- Subjects with a positive urine drug screen.
- Women who have a positive urine pregnancy test.
- Women who are currently breastfeeding are not eligible unless they are willing to stop breastfeeding for the duration of the study.
- Subjects who have tested positive and/or have exhibited symptoms consistent with SARS-CoV-2 infection during the 4 weeks prior to Screening (Visit 1).
- Any clinically significant medical history or findings as determined by the Investigator that could interfere with the objectives of the study or put the participant at risk.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Aerosol nasal de placebo
|
Nasal spray delivered 20 minutes before the PSC |
|
Experimental: Aerosol nasal de fasedienol
|
Nasal spray delivered 20 minutes before the PSC |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Subjective Units of Distress Scale (SUDS)
Periodo de tiempo: 7 days (Visit 2 to Visit 3)
|
The SUDS is a patient self-rated scale that is scored in the range of 0 to 100 (operationalized for participants in this study as 0=totally relaxed or no anxiety and 100=highest distress or anxiety ever felt). |
7 days (Visit 2 to Visit 3)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Global Impression Scale of Improvement (CGI-I)
Periodo de tiempo: 7 days (Visit 2 to Visit 3)
|
The CGI-I scale is a clinician-rated scale to assess illness improvement. The CGI-I scale includes one item being scored from 1 (best outcome) to 7 (worst outcome) with 4 being no change. |
7 days (Visit 2 to Visit 3)
|
|
Patient Global Impression of Change (PGI-C)
Periodo de tiempo: 7 days (Visit 2 to Visit 3)
|
The PGI-C is a patient self-rated scale to assess improvement. The PGI-C includes 7 items being scored from 1 (best outcome) to 7 (worst outcome) with 4 being no change. |
7 days (Visit 2 to Visit 3)
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- PH94B-CL042
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .